Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
Affiliation
CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, UK.Issue Date
1990-06
Metadata
Show full item recordAbstract
The expression of epidermal growth factor receptor (EGF-R) in 34 formalin fixed paraffin embedded specimens of malignant mesothelioma was examined using the F4 antibody. Eight samples of reactive pleura showed homogenous cytoplasmic staining with the antibody. EGF-R positive cells (greater than or equal to 5%) were found in 68% of the mesotheliomas examined. EGF-R positivity was more commonly seen in the epithelial histological subtype than in the sarcomatous or mixed subtypes. Patients with less than 5% of mesothelioma cells staining positive for EGF-R had a significantly shorter survival (median 299 days) compared with patients whose tumours had a greater number of cells positive for EGF-R (median 446 days) (P = 0.04). However, when the histological subgroup was also taken into consideration (epithelial type had a significantly longer survival than the sarcomatous or mixed) the survival difference in relation to EGF-R positivity was no longer significant (P = 0.08). EGF-R could not be used to distinguish between malignant and benign mesothelial tissue and was not an independent prognostic factor for survival.Citation
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. 1990, 61 (6):924-6 Br J CancerJournal
British Journal of CancerPubMed ID
2372497Type
ArticleLanguage
enISSN
0007-0920Collections
Related articles
- Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
- Authors: Uhlman DL, Nguyen P, Manivel JC, Zhang G, Hagen K, Fraley E, Aeppli D, Niehans GA
- Issue date: 1995 Aug
- WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
- Authors: Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J, Van Broeckhoven C, Van Marck E
- Issue date: 1997 Jan
- Immunohistochemical staining for vimentin and keratin in malignant mesothelioma.
- Authors: Churg A
- Issue date: 1985 May
- Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
- Authors: Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO
- Issue date: 2007 May 15
- Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
- Authors: Göhring UJ, Ahr A, Scharl A, Weisner V, Neuhaus W, Crombach G, Holt JA
- Issue date: 1995 Jul-Aug